Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Interferon nu, pseudogene (IFNNP1) is a genomic sequence sharing homology with type I interferon genes (such as IFNα and IFNβ), but contains sequence alterations or defects that prevent production of a functional protein. Pseudogenes like IFNNP1 are considered evolutionary remnants and do not produce a functional cytokine. They are not therapeutic targets, do not encode a receptor, and are not involved in canonical biological functions attributed to active interferons[1][2]. While some pseudogenes can transcribe RNA or potentially have regulatory effects, there is currently no evidence that IFNNP1 produces a transcribed product or plays a direct biological role[2]. It is included among the cluster of type I interferon pseudogenes on human chromosome 9[1]. Key clarification: This entry represents a pseudogene, not a functional protein or therapeutic target. It does not encode a product that can be targeted by drugs and is not involved in disease or therapeutic mechanisms[1][2].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Interferon nu 1, pseudogene (IFNNP1).